Patents Issued in July 16, 2019
-
Patent number: 10350235Abstract: The present invention provides a complex comprising at least one phosphoinositide and at least one positively charged modified polysaccharide, pharmaceutical compositions comprising the complex, methods for treatment of a disease, disorder or condition associated with impaired phosphoinositide-mediated signaling comprising administering the complex to an subject in need, and methods for delivery of a phosphoinositide into cells, comprising contacting the cells with the complex of the invention.Type: GrantFiled: August 19, 2016Date of Patent: July 16, 2019Inventor: Joseph Kost
-
Patent number: 10350236Abstract: Provided is a compound in which a group derived from chondroitin sulfate and a group derived from a steroid are covalently bonded together via a spacer represented by general formula (I). In the formula, m represents an integer of 0 or 1. Here, if m=0, R1 represents a group selected from the group consisting of electron-donating groups and steric hindrance groups. If m=1, R1 represents a group selected from the group consisting of a hydrogen atom, electron-donating groups and steric hindrance groups.Type: GrantFiled: January 8, 2016Date of Patent: July 16, 2019Assignee: Seikagaku CorporationInventors: Muneto Narita, Takahiro Hatanaka, Yuko Yoshida
-
Patent number: 10350237Abstract: A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia.Type: GrantFiled: February 4, 2014Date of Patent: July 16, 2019Assignee: University Health NetworkInventor: Ren-Ke Li
-
Patent number: 10350238Abstract: An oral care compositon is described for use in the treatment or alleviation of the symptoms of dry mouth comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient.Type: GrantFiled: July 1, 2013Date of Patent: July 16, 2019Assignee: GlaxoSmithKline Consumer Healthcare Holdings (US) LLCInventors: Gertrud Kawa, Shireen Uppal, David Urquhart
-
Patent number: 10350239Abstract: The present invention generally relates to pharmaceutical compositions containing a protease proenzyme and use thereof for treating cancer. The pharmaceutical compositions are directed to compositions comprising a protease proenzyme and an active agent, the composition being capable of providing a multi-functional approach for treating cancer. The pharmaceutical compositions are also directed to compositions comprising a first and a second protease proenzyme capable of activation at or near a surface of a tumor cell to enhance cell-to-cell adhesion of tumor cells, effect proteolysis of tumor cells, or induce tumor cell apoptosis, differentiation or immunorecognition, wherein the first protease proenzyme is chymotrypsinogen and the second protease proenzyme is trypsinogen. The pharmaceutical compositions are also directed to compositions comprising a first and second active agent each capable of inducing intracellular activity in tumor cells.Type: GrantFiled: March 17, 2017Date of Patent: July 16, 2019Assignee: Propanc Pty LtdInventors: Julian Norman Kenyon, Paul Rodney Clayton, David Tosh, Fernando Felquer, Ralf Brandt
-
Patent number: 10350240Abstract: The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.Type: GrantFiled: December 12, 2013Date of Patent: July 16, 2019Inventors: Ashok Yeshwant Gore, Milind Dixit, Ravichandran Mahalingam, Edward A. Schauer, Matthew Stewart, Rajendra Tandale, Ramsharan Singh
-
Patent number: 10350241Abstract: A trace element solution comprises at least the following metals: zinc; manganese; selenium; and copper; and which comprises a concentration of the metals of at least 90 mg/ml. The solution may comprise the following concentrations: at least 60 mg/ml zinc; at least 10 mg/ml manganese; at least 5 mg/ml selenium; and at least 15 mg/ml copper. The solution may comprise chromium, iodine and chromium.Type: GrantFiled: May 2, 2018Date of Patent: July 16, 2019Assignee: Warburton Technology LimitedInventor: William Alfred Smith
-
Patent number: 10350242Abstract: The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.Type: GrantFiled: May 2, 2012Date of Patent: July 16, 2019Assignee: IMMUNOVATIVE THERAPIES LTD.Inventor: Michael Har-Noy
-
Patent number: 10350243Abstract: The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy.Type: GrantFiled: February 19, 2016Date of Patent: July 16, 2019Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: Johannes L. Zakrzewski, Marcel R. m. Van Den Brink, Michel Sadelain
-
Patent number: 10350244Abstract: A pharmaceutical composition for the treatment of diseases in which LPS- and/or apoptosis regulation is disturbed includes colostrum and vitamin D.Type: GrantFiled: December 2, 2013Date of Patent: July 16, 2019Inventors: Martin Gasser, Ana Maria Waaga-Gasser
-
Patent number: 10350245Abstract: A platform for ex vivo isolation, production, and formulation of genetically-modified cells is described. The platform utilizes a software-enabled point-of-care and/or portable device making gene therapy more widely available.Type: GrantFiled: January 21, 2016Date of Patent: July 16, 2019Assignee: Fred Hutchinson Cancer Research CenterInventors: Jennifer E. Adair, Hans-Peter Kiem
-
Patent number: 10350246Abstract: The present application discloses the use of light-gated cation-selective channelrhodopsins (Ch Rs) for the optogenetic control of the secretion of a polypeptide of interest in adipocytes. Engineered adipocytes comprising a channelrhodopsin (ChR) polypeptide, and/or a nucleic acid encoding same, and a secretory polypeptide precursor comprising a bioactive polypeptide and a signal peptide suitable for secretion of the bioactive polypeptide by the engineered adipocytes, and/or a nucleic acid encoding same, are disclosed. The use of such engineered adipocytes for the management or treatment of diseases/conditions in which the secretion of a polypeptide of interest is beneficial, such as the secretion of insulin in diabetic patients, is also disclosed.Type: GrantFiled: November 6, 2015Date of Patent: July 16, 2019Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventor: Peter Edward Light
-
Patent number: 10350247Abstract: The invention relates to a pharmaceutical composition consisting of snail slime of Helix aspersa muller (Cryptophalus aspersus) (5% to 50%), chamomile extract (5% to 10%), honey (5% to 10%), and additives and/or pharmaceutically accepted excipients to form a formulation having low, intermediate or high viscosity (1 to 1000 Pa-s). By dipping a patch or bandage of gauzy fabric into the composition in the form of a lotion, shampoo, soap, cream or gel, the composition is applied on lesions caused by psoriasis. The composition can also contain natural extracts, such as marigold extract, propolis, and vegetable oils. The invention also claims a method for obtaining the composition and the use thereof to prepare a drug or device for preventing, treating or curing psoriasis lesions on the head, the skin of the body or of the face.Type: GrantFiled: September 12, 2014Date of Patent: July 16, 2019Assignee: MUCIDERM S.A.Inventor: Elmo Moreno Gonzalez
-
Patent number: 10350248Abstract: Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity and obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity and obesity-related diseases, and a method for treatment or prevention of obesity and obesity-related diseases.Type: GrantFiled: September 30, 2014Date of Patent: July 16, 2019Assignee: RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINEInventors: Guang Ning, Jie Hong, Weiqing Wang, Ruixin Liu, Jiqiu Wang
-
Patent number: 10350249Abstract: Methods of reducing milk glycans, and thus enteric pathogens that use such glycans as carbon sources, in the gut of nursing mammals.Type: GrantFiled: December 11, 2015Date of Patent: July 16, 2019Assignee: The Regents of the University of CaliforniaInventors: David A. Mills, Steven A. Frese
-
Patent number: 10350250Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.Type: GrantFiled: May 30, 2018Date of Patent: July 16, 2019Assignee: Vedanta Biosciences, Inc.Inventors: Jessica Schneider, Yun-Gi Kim, Bernat Olle, Shilpa Reddy, Jason Norman, Juan Patarroyo
-
Patent number: 10350251Abstract: Disclosed here are compositions comprising powdered hemp seed, an emulsifier/dispersant such as lecithin (particularly soya lecithin), cannabis, and optionally other additives and excipients. Also described are methods of making the compositions. The compositions may be used, for instance, in the treatment of pain and for their anti-emetic (anti-nausea and anti-vomiting) properties, as well as for the treatment of anorexia and appetite enhancement. Kits containing the compositions, arranged for proper sequential dosing, and optionally including instructions for use are also disclosed.Type: GrantFiled: March 28, 2013Date of Patent: July 16, 2019Inventor: Keith Gerald Freeman
-
Patent number: 10350252Abstract: The present invention relates to the use of cocoa polyphenols, in particular, procyanidin(s) in the treatment or prevention of eosinophilic esophagitis.Type: GrantFiled: September 22, 2014Date of Patent: July 16, 2019Assignee: Nestec S.A.Inventors: Carine Blanchard, Sebastien Holvoet
-
Patent number: 10350253Abstract: A composition and method for the use of Panax quinquefolius for the attenuation of Cannabis-induced dysphoria where dosage can be effectively administered in a gum base cold pressed into a tablet containing at least 300 mg of Panax quinquefolius and Maltitol, Sorbitol, Isomalt, Xylitol, natural & artificial flavors, vegetarian magnesium stearate, Sucralose and Silicon dioxide.Type: GrantFiled: January 5, 2018Date of Patent: July 16, 2019Assignee: ENGEN MEDICAL CORPORATIONInventors: Paul Epner, Richard Zimmer, III, Bill W. Massey
-
Patent number: 10350254Abstract: The present invention relates to a composition containing a fraction of a Mouton Radicis Cortex extract, which can be advantageously used in the prevention or treatment of liver diseases. In the present invention, it was specifically verified that the use of the composition can effectively reduce the blood ALT concentration, inhibit the increase of TLR4 or IL-1? protein expression in the liver, and also inhibit the lipid peroxidation in the liver, and thus, it is expected that the composition can attain target therapy through a more fundamental approach in the prevention or treatment of liver diseases.Type: GrantFiled: October 17, 2016Date of Patent: July 16, 2019Assignee: Research & Business Foundation Sungkyunkwan UniversityInventors: Sun-Mee Lee, Hong-Ik Cho
-
Patent number: 10350255Abstract: The present invention describes extracts of Polygonum cuspidatum and related compositions that are capable of photodynamic inactivation (PDI) of microorganisms such as bacteria, viruses, fungi, and protozoa, and capable of killing or inactivating cancer cells. The present invention further describes methods of using said Polygonum cuspidatum extracts and photodynamic inactivation (PDI) as a therapy for the treatment of microbial infection and as well as the use of Polygonum cuspidatum extract and related compositions as photodynamic therapy agents for the treatment of cancer.Type: GrantFiled: September 30, 2016Date of Patent: July 16, 2019Assignee: PhotoDynamic Inc.Inventor: Sherri McFarland
-
Patent number: 10350256Abstract: The present invention relates to compositions comprising black cumin (Nigelia sativa seed) oil, olive oil, tea tree (Melaleuca alternifolia) oil, cocoa butter, vitamin A or a derivative thereof, and vitamin B12 or a derivative thereof. The compositions of the present invention can be advantageously used in the in the treatment of dermatological conditions, disorders or diseases, in particular inflammatory dermatological diseases such as psoriasis.Type: GrantFiled: February 21, 2017Date of Patent: July 16, 2019Assignee: Veit Hoermann Gesellschaft Für Unternehmenskommunikation mbHInventor: Thaher Kamal
-
Patent number: 10350257Abstract: The present invention provides a pharmaceutical or health functional food containing, as an active ingredient, a complex extract of Crataegi Fructus and Citri Pericarpium. The complex extract has the effects of reducing body weight and lipids in blood vessels.Type: GrantFiled: June 21, 2013Date of Patent: July 16, 2019Assignee: NEUMEDInventors: Juyeon Park, Dong Wook Lim, Mikyung Song
-
Patent number: 10350258Abstract: Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising an Uncaria tomentosa extract and an oolong tea extract. Compositions containing an Uncaria tomentosa extract in combination with an oolong tea extract.Type: GrantFiled: August 4, 2017Date of Patent: July 16, 2019Assignee: Cognitive Clarity Inc.Inventors: Judy Cam, Thomas Lake, Qubai Hu, Joel Cummings, Alan D Snow
-
Patent number: 10350259Abstract: The invention relates to extracts produced from sugar cane processing stream products having desirable properties and health benefits. More particularly the invention relates to sugar cane derived extracts obtained from molasses, methods of producing the extracts, and uses of the extracts for management of insulin resistant conditions or subjects predisposed to such conditions, such as type 2 diabetes. The sugar cane derived extracts of the invention are enriched in polyphenols and the administration of the sugar cane derived extract regulates postprandial glucose response and insulin response and lowering those responses, to avoid the subject becoming hypoglycaemic.Type: GrantFiled: August 15, 2014Date of Patent: July 16, 2019Assignee: THE PRODUCT MAKERS (AUSTRALIA) PTY LTDInventors: Leodevico Luna Ilag, Timothy Peter Ellis, Alison Grace Wright
-
Patent number: 10350260Abstract: The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.Type: GrantFiled: July 8, 2015Date of Patent: July 16, 2019Assignee: Susavion Biosciences, Inc.Inventors: Laura L. Eggink, J. Kenneth Hoober
-
Patent number: 10350261Abstract: Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.Type: GrantFiled: June 9, 2015Date of Patent: July 16, 2019Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Charles T. Esmon, Jun Xu, Xiaomei Zhang
-
Patent number: 10350262Abstract: The invention relates, in part, to compounds, compositions, and methods useful to treat cancer in cells and subjects. In some aspects the invention includes contacting a cancer cell with one or more exogenous methylation-controlled J protein (MCJ) agonist compounds to increase sensitivity of the cancer cell to one or more chemotherapeutic agents. In certain aspects the invention includes compounds and methods useful to kill cancer cells.Type: GrantFiled: February 18, 2016Date of Patent: July 16, 2019Assignee: University of Vermont and State Agricultural CollegeInventors: Mercedes Rincon, Thomas Roberts, Tina Thornton
-
Patent number: 10350263Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.Type: GrantFiled: February 13, 2019Date of Patent: July 16, 2019Assignee: The University of KansasInventors: Peter S. N. Rowe, Aline Martin, Nicolae Valentin David, M. Laird Forrest, Kenneth Ryan Moulder, Shuang Cai, Daniel J. Aires
-
Patent number: 10350264Abstract: Described herein are methods of modulating autophagic targeting of ferritin in a cell, wherein the method comprises modulating the level and/or activity of nuclear receptor coactivator 4 (NCOA4) in the cell. Also provided are related methods of treatment.Type: GrantFiled: March 27, 2015Date of Patent: July 16, 2019Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College, Beth Israel Deaconess Medical Center, Inc., The Brigham & Women's Hospital, Inc.Inventors: Alec C. Kimmelman, Joseph D. Mancias, Jeffrey Wade Harper
-
Patent number: 10350265Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.Type: GrantFiled: September 30, 2016Date of Patent: July 16, 2019Assignee: The Regents of the University of Colorado, a body corporateInventors: Xiao-jing Wang, Yosef Refaeli, Qinghong Zhang
-
Patent number: 10350266Abstract: The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein alone or in combination with IL-2 and/or an immune checkpoint inhibitor. The invention also provides composition for use in such methods.Type: GrantFiled: May 30, 2017Date of Patent: July 16, 2019Assignee: NODUS THERAPEUTICS, INC.Inventors: Jennifer R. Cochran, Karl Dane Wittrup
-
Patent number: 10350267Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.Type: GrantFiled: February 20, 2018Date of Patent: July 16, 2019Assignee: the regents of the university of californiaInventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
-
Patent number: 10350268Abstract: Medical use of alpha-1-microglobulin (A1M) in the treatment or prophylaxis of diseases wherein oxidative stress is a responsible factor in the progress of the disease. Notably, the present invention relates to the medical use of alpha-1-microglobulin in the treatment or prophylaxis of diseases or conditions associated with the presences of free radicals and/or free haemoglobin in the subject.Type: GrantFiled: July 17, 2009Date of Patent: July 16, 2019Assignee: A1M PHARMA ABInventors: Bo Åkerström, Stefan Hansson, Martin Lennarth Olsson, Magnus Gram
-
Patent number: 10350269Abstract: The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases.Type: GrantFiled: October 25, 2016Date of Patent: July 16, 2019Assignee: MIND-NRG SARLInventor: André Schrattenholz
-
Patent number: 10350270Abstract: Interleukin-15 muteins and other interleukin-15-related molecules are described, as well as methods of identifying interleukin-15 muteins and other interleukin-15-related molecules. Also described herein are modifications of the foregoing, which modifications may enhance a property (e.g., half-life) of the muteins or other molecules compared to human interleukin-15. Pharmaceutical compositions and methods of use are also described herein.Type: GrantFiled: October 12, 2015Date of Patent: July 16, 2019Assignee: Armo Biosciences, Inc.Inventor: Scott McCauley
-
Patent number: 10350271Abstract: Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides towers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.Type: GrantFiled: April 26, 2016Date of Patent: July 16, 2019Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, V.V.I., FYZIOLOGICKY USTAV AKADEMIE VED CR, V.V.I.Inventors: Lenka Maletinska, Blanka Zelezna, Jaroslav Kunes, Veronika Prazienkova
-
Patent number: 10350272Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.Type: GrantFiled: January 7, 2016Date of Patent: July 16, 2019Assignee: KeyBioscience AGInventors: Morten Karsdal, Kim Henriksen, Kim Vietz Andreassen, Sofie Gydesen, Sara Toftegaard Hjuler
-
Patent number: 10350273Abstract: The present invention refers to a GPR101 inhibitor, antagonist or inverse agonist or inverse agonist for use in preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of acromegaly and gigantism. Further, the present invention provides a GPR101 agonist for use in preventive and/or therapeutic treatment of disorders selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion and to methods for preventive and/or therapeutic treatment of diseases selected from the group consisting of dwarfism, short stature, hypopituitarism and a disease of low levels of pituitary hormone secretion wherein to a subject GPR101 agonist is administered.Type: GrantFiled: November 12, 2015Date of Patent: July 16, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Université de Liége and Centre Hospitalier Universitaire De LiégeInventors: Albert Beckers, Adrian Francis Daly, Fabio Rueda Faucz, Constantine A. Stratakis, Giampaolo Trivellin
-
Patent number: 10350274Abstract: A method prepares a solution of human albumin by reducing dissolved oxygen in a solution of albumin until a concentration of oxygen equal to or less than 0.5 ppm is achieved. A solution of human albumin having a redox state closer to the redox state of the albumin present in human plasma can be achieved.Type: GrantFiled: May 28, 2015Date of Patent: July 16, 2019Assignee: GRIFOLS, S.A.Inventors: Juan Ignacio Jorquera Nieto, Ana Maria Ortiz Fernandez, Montserrat Costa Rierola
-
Patent number: 10350275Abstract: A method is disclosed for decreasing or retarding an increase in the size of a localized or metastatic tumor by using a combination of an immune stimulating cytotoxic gene therapy and immune-checkpoint modulating agent, in conjunction with other therapies, including radiation therapy, chemotherapy, surgery, and immunotherapies.Type: GrantFiled: September 19, 2014Date of Patent: July 16, 2019Assignee: Advantagene, Inc.Inventor: Carlos Estuardo Aguilar-Cordova
-
Patent number: 10350276Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.Type: GrantFiled: December 10, 2018Date of Patent: July 16, 2019Assignee: Novo Nordisk HealthCare AGInventor: Ulla Hedner
-
Patent number: 10350277Abstract: The present invention relates to methods of producing chondrocytes, improving the phenotype of a chondrocyte population, promoting chondrogenesis, maintaining a cell population in a differentiated state or increasing the number of cells of a population in a differentiated state, producing a population of differentiated cells, and treating certain diseases or disorders. Each of these methods involves treating a cell population with, and/or culturing a cell population in, a ceramidase.Type: GrantFiled: September 7, 2012Date of Patent: July 16, 2019Assignee: Icahn School of Medicine at Mount SinaiInventors: Edward H. Schuchman, Calogera M. Simonaro
-
Patent number: 10350278Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of celiac disease or a related disorder. Also described herein is a method for treating a subject with celiac disease or a related disorder using digestive enzymes and their derivatives to alleviate the symptoms of celiac disease or a related disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of celiac disease or a related disorder.Type: GrantFiled: March 15, 2013Date of Patent: July 16, 2019Assignee: CUREMARK, LLCInventors: Joan M. Fallon, Matthew Heil, James Szigethy, James J. Fallon
-
Patent number: 10350279Abstract: The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.Type: GrantFiled: June 23, 2015Date of Patent: July 16, 2019Assignee: JW CREAGENE INC.Inventors: Yong-Soo Bae, Jun-Eui Park, Yun-Ju Woo, Jin-Ah Jang
-
Patent number: 10350280Abstract: The invention describes a method for identifying T-cell activating neo-epitopes from all genetically altered proteins. The mutated proteins contribute to neo-epitopes after they are proteolytically degraded within antigen presenting cells, such as dendritic cells and macrophages.Type: GrantFiled: October 23, 2017Date of Patent: July 16, 2019Assignee: MedGenome Inc.Inventors: Amitabha Chaudhuri, Ravi Gupta, Priyanka Shah, Malini Manoharan, Kiran V. Paul, Rohit Gupta
-
Patent number: 10350281Abstract: The invention discloses a method for producing a single bacterial strain culture of Histomonas meleagridis (H. meleagridis), the method being characterised by the following steps: (a) providing a xenic culture of H. meleagridis comprising H. meleagridis cells with a wild type bacterial flora, (b) treating the xenic culture with a mixture of antibiotics thereby killing the wild type bacterial flora, (c) centrifuging and washing the H. meleagridis cells, (d) controlling effectiveness of step (b), (e) resuspending the washed H. meleagridis cells, (f) adding one or more single bacterial strain(s) to the resuspended H. meleagridis cells, and (g) culturing the one or more single bacterial strain(s) with the resuspended H. meleagridis cells so as to obtain a single bacterial strain culture of H. meleagridis.Type: GrantFiled: November 2, 2017Date of Patent: July 16, 2019Assignee: VETERINARMEDIZINISCHE UNIVERSITAT WIENInventors: Michael Hess, Petra Ganas
-
Patent number: 10350282Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: GrantFiled: October 25, 2016Date of Patent: July 16, 2019Assignee: The Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
-
Patent number: 10350283Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: GrantFiled: September 19, 2018Date of Patent: July 16, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventor: Martine Marchand
-
Patent number: 10350284Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.Type: GrantFiled: March 31, 2019Date of Patent: July 16, 2019Assignees: Lior Carmon, VAXIL BIOTHERAPEUTICS LTD.Inventor: Lior Carmon